The Central Bank of Nigeria has amended guidelines for the operation of the Healthcare Sector Research and Development Intervention Scheme.
The scheme was earlier introduced in May 2020 to help strengthen the public healthcare system with innovative financing of research and development as a response to the Coronavirus Disease.
Released on Wednesday, the amended HSRDIS framework, which was included one nominee from the National Biotechnological Development Agency in the composition of the Body of Experts, which is responsible for the review and evaluation of submitted research proposals as well as recommendation on financing the research and development projects.
The new guidelines further stated that going forward, candidate vaccines undergoing “late pre-clinical and early clinical” testing or trials shall be eligible for consideration under the scheme if considered to have high potential to cross the clinical trial stage and prospects of scale by the BoEs.
It also stipulated that inventions arising from HSRDIS financed research and development projects must be reported to the CBN that funded the grants.
